Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma

Nuclear Medicine Communications

Volumn 34, Issue 8, 2013, Pages 749-757

  Pant, Vineet ^a   Sen, Ishita B ^a   Soin, Arvinder S ^b  

^a Fortis Memorial Research Institute   (India)

^b Institute of Liver Transplantation and Regenerative Medicine   (India)

Author keywords

18F FDG PET CT; Molecular signature; Role in hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PET SCANNER; PORTAL VEIN THROMBOSIS; PREDICTION; PRIMARY TUMOR; RETROSPECTIVE STUDY; WHOLE BODY PET; COMPUTER ASSISTED TOMOGRAPHY; LIVER TUMOR; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; LIVER NEOPLASMS;

ADULT; AGED; BIOLOGICAL TRANSPORT; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879959828     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283622eef     Document Type: Article

References (36)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32:225-237.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
4. Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 2002; 10:31-52.
5. Lee KHY, O'Malley ME, Kachura JR, Haider M, Hanbidge A. Hepatocellular carcinoma: imaging and imaging guided intervention. Am J Roentgenol 2003; 180:1015-1022.
6. Semelka RC, Martin DR, Balci C, Lance T. Focal hepatic lesions: comparison of dual phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001; 13:397-401.
7. Abe K, Baba S, Kaneko K, Isoda T, Yabuuchi H, Sasaki M, et al. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer. Clin Imaging 2009; 33:90-95.
8. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009; 361:32-39.
9. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23:4652-4661.
10. Wu D, Gambhir SS. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer 2003; 4:S55-S63.
11. Choi M, Heilbrun LK,Venkatramanamoorthy R, Lawhorn Crews JM, Zalupski MM, Shields AF. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemoradiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 2010; 33:257-261.
12. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009; 50:97S-105S.
13. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17:115-122.
14. Inohara H, Enomoto K, Tomiyama Y, Higuchi I, Inoue T. Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma. Mol Imaging Biol 2010; 12:89-97.
15. Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C. Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2010; 17:247-253.
16. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009; 115:3196-3203.
17. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G. 18- Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003; 7:953-959.
18. Wudel LJ Jr, Delbeke D, Morris D, Rice M,Washington MK, Shyr Y, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003; 69:117-124, discussion 124-126.
19. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008; 33:1047-1054.
20. Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, et al. Preoperative positron emission tomography with fluorine-18- fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006; 30:1736-1741.
21. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB. The role of 18F-FDGPET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12:1655-1660.
22. Yen YH, Changchien CS, Wang JH. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dise 2009; 41:431-441.
23. Yau T, Yao JY, Chan P, Fan ST. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy. Cancer 2008; 113:2742-2751.
24. Chen CH, Hu FC, Huang GT. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - analysis of 2010 Taiwanese patients. Eur J Cancer 2009; 45:1630-1639.
25. Lu W, Dong J, Huang Z, Guo D, Liu Y. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 2008; 23:1874-1878.
26. Farinati F, Sergio A, Baldan A, Giacomin A, Di Nolfo MA, Del Poggio P, et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009; 9:33-36.
27. Zhou L, Rui JA, Wang SB. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV related hepatocellular carcinoma after radical hepatectomy. J Surg Res 2010; 159:538-544.
28. Ho CL, Yu CH, Yeung DWC. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-222.
29. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to F-18-FDG uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31:1621-1630.
30. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43:173-180.
31. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
32. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med 2005; 46:1753-1759.
33. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) 2003; 5:243-250.
34. Khan MA, Combs CS, Brunt EM, Lowe VJ,Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-797.
35. Shin DY, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 2010; 10:1454-1456.
36. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228:479-490.